ReviewExperimental and clinical psychopharmacology2025
Looking beyond traditional pain outcomes to better evaluate cannabis's true potential and limitations in chronic pain management.
Review in Experimental and clinical psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cannabis is increasingly used for managing chronic pain, despite the low quality and inconsistency of most evidence from randomized controlled trials and the divergent expert opinions and guidelines issued by academic societies. In this perspective piece, we suggest a way forward. The clinical trials have focused on traditional chronic pain outcomes (such as pain severity and interference, as well as physical and emotional functioning). However, qualitative studies suggest that many individuals perceive cannabis as beneficial not because it directly reduces pain but because it alters their psychological responses to it and improves other important outcomes, such as role and social functioning, sleep quality, and opioid substitution, which are largely overlooked in clinical trials of cannabis for chronic pain. We contend that the true clinical potential and limitations of cannabis for pain management may be fundamentally misunderstood if research continues to prioritize conventional chronic pain outcomes alone. We call for the integration of perspectives from people with lived experience in identifying meaningful clinical outcomes for future clinical trials on cannabis and chronic pain. Such a shift would clarify cannabis's true benefits and limitations, ultimately guiding more nuanced, evidence-based, and personalized treatment approaches for chronic pain. (PsycInfo Database Record (c) 2025 APA, all rights reserved).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.